Journal of Clinical Oncology, Vol 15, 3121-3128, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium

MR Fetell, SA Grossman, JD Fisher, B Erlanger, E Rowinsky, J Stockel and S Piantadosi
Department of Neurology, Columbia University, New York, NY, USA. jfisher@welchlink.welch.jhu.edu

PURPOSE: The purpose of this study was to determine the response rate of paclitaxel administered at maximal tolerated doses (MTD) in patients with newly diagnosed glioblastoma multiform. PATIENTS AND METHODS: All patients in this multicenter study were 45 years or older and had measurable residual tumor on postoperative MRI scans. Up to 3 cycles of paclitaxel were administered as a continuous 96-hour intravenous infusion prior to radiation, provided that the tumor did not enlarge on serial MRIs. The initial 10 patients were treated with the previously recommended phase II dose of 140 mg/m2. Less than anticipated toxicity led to the development of a phase I/II study in 24 patients in which paclitaxel doses were escalated separately in patients receiving (+EIAED) or not receiving (-EIAED), concomitant enzyme-inducing antiepileptic drugs. Paclitaxel plasma steady-state concentrations (Css) were measured during the first cycle of chemotherapy. Response was the primary efficacy endpoint for this study, although survival was also assessed. RESULTS: The MTD was 140 mg/m2 in the -EIAED, and 200 mg/m2 in the +EIAED patient groups. The mean Css for the -EIAED patients treated at 140 mg/m2 was 38 nM, whereas the mean Css for +EIAED patients were 17 nm at 140 mg/m2, 27 nM at 175 mg/m2, 46 nM at 200 mg/m2, and 51 nM at 230 mg/m2. One patient, who had a verified partial response, had his diagnosis changed to an anaplastic oligodendroglioma on subsequent central neuropathologic review. None of the 15 assessable glioblastoma patients treated at or above the MTD doses showed a radiographic response to paclitaxel. The median survival of eligible patients on this protocol was 355 days (95% CI, 255 to 485 days), which is similar to the survival of comparable patients treated with conventional therapy. CONCLUSIONS: These results suggest that (1) paclitaxel given as a 96-hour infusion at the MTD has minimal activity in patients with untreated glioblastoma, (2) the concomitant administration of EIAEDs alters the pharmacology of paclitaxel, resulting in a lower Css, reduced systemic toxicity, and higher dose requirements, (3) this study design, in which a new agent is given prior to radiation therapy (with serial monitoring of MRI), did not adversely affect survival in this patient population.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. A. Grossman, J. Olson, T. Batchelor, D. Peereboom, G. Lesser, S. Desideri, X. Ye, T. Hammour, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma Neuro-oncol, April 1, 2008; 10(2): 190 - 198. [Abstract] [Full Text] [PDF]

				R. Lustig, T. Mikkelsen, G. Lesser, S. Grossman, X. Ye, S. Desideri, J. Fisher, J. Wright, and the New Approaches to Brain Tumor Therapy CNS Cons Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease Neuro-oncol, January 1, 2008; 10(6): 1004 - 1009. [Abstract] [Full Text] [PDF]

				R. Michelucci Optimizing therapy of seizures in neurosurgery Neurology, December 26, 2006; 67(12_suppl_4): S14 - S18. [Abstract] [Full Text]

				R. L. Fine, J. Chen, C. Balmaceda, J. N. Bruce, M. Huang, M. Desai, M. B. Sisti, G. M. McKhann, R. R. Goodman, J. S. Bertino Jr., et al. Randomized study of Paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin. Cancer Res., October 1, 2006; 12(19): 5770 - 5776. [Abstract] [Full Text] [PDF]

				T. F. Cloughesy, P. Y. Wen, H. I. Robins, S. M. Chang, M. D. Groves, K. L. Fink, L. Junck, D. Schiff, L. Abrey, M. R. Gilbert, et al. Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study J. Clin. Oncol., August 1, 2006; 24(22): 3651 - 3656. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]

				R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, February 1, 2006; 11(2): 165 - 180. [Abstract] [Full Text] [PDF]

				T. F. Cloughesy, J. Kuhn, H. I. Robins, L. Abrey, P. Wen, K. Fink, F. S. Lieberman, M. Mehta, S. Chang, A. Yung, et al. Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study J. Clin. Oncol., September 20, 2005; 23(27): 6647 - 6656. [Abstract] [Full Text] [PDF]

				M. Brada, S. Ashley, A. Dowe, A. Gonsalves, A. Huchet, G. Pesce, M. Reni, F. Saran, B. Wharram, M. Wilkins, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide Ann. Onc., June 1, 2005; 16(6): 942 - 949. [Abstract] [Full Text] [PDF]

				S. Phuphanich, S. D. Baker, S. A. Grossman, K. A. Carson, M. R. Gilbert, J. D. Fisher, and M. A. Carducci Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study Neuro-oncol, April 1, 2005; 7(2): 177 - 182. [Abstract] [PDF]

				S. A. Grossman, J. B. Alavi, J. G. Supko, K. A. Carson, R. Priet, F. A. Dorr, J. S. Grundy, and J. T. Holmlund Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-{alpha} delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas Neuro-oncol, January 1, 2005; 7(1): 32 - 40. [Abstract] [PDF]

				G. Singh, P. H. Driever, and J. W. Sander Cancer risk in people with epilepsy: the role of antiepileptic drugs Brain, January 1, 2005; 128(1): 7 - 17. [Abstract] [Full Text] [PDF]

				F. M. Boyle, S. L. Eller, and S. A. Grossman Penetration of intra-arterially administered vincristine in experimental brain tumor Neuro-oncol, October 1, 2004; 6(4): 300 - 306. [Abstract] [PDF]

				E. T. Wong and A. Berkenblit The Role of Topotecan in the Treatment of Brain Metastases Oncologist, February 1, 2004; 9(1): 68 - 79. [Abstract] [Full Text] [PDF]

				T. T. Batchelor, M. R. Gilbert, J. G. Supko, K. A. Carson, L. B. Nabors, S. A. Grossman, G. J. Lesser, T. Mikkelsen, S. Phuphanich, and for the NABTT CNS Consortium Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11 Neuro-oncol, January 1, 2004; 6(1): 21 - 27. [Abstract] [PDF]

				M. R. Gilbert, J. G. Supko, T. Batchelor, G. Lesser, J. D. Fisher, S. Piantadosi, and S. Grossman Phase I Clinical and Pharmacokinetic Study of Irinotecan in Adults with Recurrent Malignant Glioma Clin. Cancer Res., August 1, 2003; 9(8): 2940 - 2949. [Abstract] [Full Text] [PDF]

				K. W. Li, W. Dang, B. M. Tyler, G. Troiano, T. Tihan, H. Brem, and K. A. Walter Polilactofate Microspheres for Paclitaxel Delivery to Central Nervous System Malignancies Clin. Cancer Res., August 1, 2003; 9(9): 3441 - 3447. [Abstract] [Full Text] [PDF]

				M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]

				S. A. Grossman, A. O'Neill, M. Grunnet, M. Mehta, J. L. Pearlman, H. Wagner, M. Gilbert, H. B. Newton, and R. Hellman Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394 J. Clin. Oncol., April 15, 2003; 21(8): 1485 - 1491. [Abstract] [Full Text] [PDF]

				E. Raymond, M. Fabbro, V. Boige, O. Rixe, M. Frenay, G. Vassal, S. Faivre, E. Sicard, C. Germa, J. M. Rodier, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma Ann. Onc., April 1, 2003; 14(4): 603 - 614. [Abstract] [Full Text] [PDF]

				S. A. Grossman, S. Phuphanich, G. Lesser, J. Rozental, L. B. Grochow, J. Fisher, and S. Piantadosi Toxicity, Efficacy, and Pharmacology of Suramin in Adults With Recurrent High-Grade Gliomas J. Clin. Oncol., July 1, 2001; 19(13): 3260 - 3266. [Abstract] [Full Text] [PDF]

				N. L. Antunes Topical Review: Acute Neurologic Complications in Children With Systemic Cancer J Child Neurol, November 1, 2000; 15(11): 705 - 716. [Abstract] [PDF]

				M. J. Glantz, B. F. Cole, P. A. Forsyth, L. D. Recht, P. Y. Wen, M. C. Chamberlain, S. A. Grossman, and J. G. Cairncross Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, May 23, 2000; 54(10): 1886 - 1893. [Full Text] [PDF]

				F. Hochberg, S. A. Grossman, T. Mikkelsen, M. Glantz, J. D. Fisher, S. Piantadosi, and the NABTT CNS Consortium Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma Neuro-oncol, January 1, 2000; 2(1): 29 - 33. [Abstract] [PDF]

				M. A. Villalona-Calero, T. Petit, J. Kuhn, P. Cobb, M. Kraynak, S. G. Eckhardt, R. Drengler, C. Simmons, P. Santabarbara, D. D. Von Hoff, et al. A Phase I and Pharmacological Study of Protracted Infusions of Crisnatol Mesylate in Patients with Solid Malignancies Clin. Cancer Res., November 1, 1999; 5(11): 3369 - 3378. [Abstract] [Full Text] [PDF]

				N. G. Avgeropoulos and T. T. Batchelor New Treatment Strategies for Malignant Gliomas Oncologist, June 1, 1999; 4(3): 209 - 224. [Abstract] [Full Text]

				W. R. Shapiro Current Therapy for Brain Tumors: Back to the Future Arch Neurol, April 1, 1999; 56(4): 429 - 432. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky On Pushing the Outer Edge of the Outer Edge of Paclitaxel's Dosing Envelope Clin. Cancer Res., March 1, 1999; 5(3): 481 - 486. [Full Text] [PDF]